HopeStage
Back to all studies
CompletedNCT01738867

Reward and Brain Responses to Alcohol-Related Medicines in Social Drinkers

About this titleRead the official source — NCT01738867
Medication studyAges 18–65United KingdomAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
CambridgeSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: December 12, 2012
Recruitment status
Completed
Enrollment listed in the registry
56
Sponsor
GlaxoSmithKline
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 65 Years
Official registry ID
NCT01738867
Official title
Show the full official title

A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Cambridge

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is GlaxoSmithKline.

Did this study involve medication?

Yes. The study involved medication, including GSK1521498, Naltrexone (NTX) and Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies